A intramuscular injection of DS-5670a or Comirnaty twice in total

2 trials

Sponsors

Inoguchi Akihiro

Conditions

Prevention of infectious disease by Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)

Phase 3

A Phase 3, Randomized, Active-Comparator, Observer-Blind, Non-Inferiority Study of DS-5670a in Adults Aged 18 Years and Older

Active, not recruitingJPRN-jRCT2031220264

Inoguchi AkihiroPrevention of infectious disease by Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)

Start: 2022-09-01Target: 420Updated: 2026-06-29

A phase III, randomized, active-comparator, non-inferiority study to demonstrate the Immunogenicity and Safety of DS-5670a in children 12 through 17 years of age.

Active, not recruitingJPRN-jRCT2031220400

Inoguchi AkihiroPrevention of infectious disease by Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)

Start: 2022-11-12Target: 450Updated: 2026-06-29